Wells Fargo & Company MN Increases Stake in AngioDynamics, Inc. (NASDAQ:ANGO)

Wells Fargo & Company MN raised its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 35.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,715 shares of the medical instruments supplier’s stock after buying an additional 6,200 shares during the period. Wells Fargo & Company MN’s holdings in AngioDynamics were worth $217,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Segall Bryant & Hamill LLC boosted its holdings in AngioDynamics by 55.3% in the fourth quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier’s stock valued at $12,963,000 after purchasing an additional 503,713 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in AngioDynamics by 293.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 352,544 shares of the medical instruments supplier’s stock worth $3,229,000 after purchasing an additional 263,034 shares during the period. JPMorgan Chase & Co. raised its position in AngioDynamics by 46.0% in the 4th quarter. JPMorgan Chase & Co. now owns 807,483 shares of the medical instruments supplier’s stock valued at $7,397,000 after purchasing an additional 254,322 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of AngioDynamics by 69.0% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 389,053 shares of the medical instruments supplier’s stock valued at $3,564,000 after buying an additional 158,897 shares during the period. Finally, Royce & Associates LP grew its position in shares of AngioDynamics by 13.5% during the fourth quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier’s stock worth $10,254,000 after buying an additional 133,312 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Price Performance

NASDAQ:ANGO opened at $9.27 on Friday. AngioDynamics, Inc. has a 12 month low of $5.47 and a 12 month high of $13.50. The firm has a market capitalization of $376.31 million, a PE ratio of -1.65 and a beta of 0.58. The business’s fifty day moving average price is $9.43 and its 200 day moving average price is $9.29.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, April 2nd. The medical instruments supplier reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.16. The business had revenue of $72.00 million for the quarter, compared to the consensus estimate of $70.30 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The business’s revenue was down 4.3% on a year-over-year basis. As a group, equities analysts anticipate that AngioDynamics, Inc. will post -0.37 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price (up previously from $15.00) on shares of AngioDynamics in a report on Monday, April 7th.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.